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Purpose: The biologic relevance of human connective tissue growth factor (hCTGF) for primary human tenon fibroblasts
(HTFs) was investigated by RNA expression profiling using affymetrixTM oligonucleotide array technology to identify
genes that are regulated by hCTGF.
Methods: Recombinant hCTGF was expressed in HEK293T cells and purified by affinity and gel chromatography.
Specificity and biologic activity of hCTGF was confirmed by biosensor interaction analysis and proliferation assays. For
RNA expression profiling HTFs were stimulated with hCTGF for 48h and analyzed using affymetrixTM oligonucleotide
array technology. Results were validated by real time RT–PCR.
Results: hCTGF induces various groups of genes responsible for a wound healing and inflammatory response in HTFs.
A  new  subset  of  CTGF  inducible  inflammatory  genes  was  discovered  (e.g.,  chemokine  [C-X-C  motif]  ligand  1
[CXCL1], chemokine [C-X-C motif] ligand 6 [CXCL6], interleukin 6 [IL6], and interleukin 8 [IL8]). We also identified
genes that can transmit the known biologic functions initiated by CTGF such as proliferation and extracellular matrix
remodelling. Of special interest is a group of genes, e.g., osteoglycin (OGN) and osteomodulin (OMD), which are known
to play a key role in osteoblast biology.
Conclusions: This study specifies the important role of hCTGF for primary tenon fibroblast function. The RNA expression
profile  yields  new  insights  into  the  relevance  of  hCTGF  in  influencing  biologic  processes  like  wound  healing,
inflammation, proliferation, and extracellular matrix remodelling in vitro via transcriptional regulation of specific genes.
The results suggest that CTGF potentially acts as a modulating factor in inflammatory and wound healing response in
fibroblasts of the human eye.
The connective tissue growth factor (CTGF) belongs to
the CCN (cyr61, ctgf, nov) protein family. The known six
members  of  this  family  (CTGF,  cysteine-rich  angiogenic
inducer  61  [Cyr61],  nephroblastoma  overexpressed  gene
[Nov], and WNT1 inducible signaling pathway protein 1-3
[WISP1–3]) share a high amino acid sequence homology and
are  composed  of  four  domains  (except  WISP-2)  [1,2],  a
insulin like growth factor-binding-domain, a von Willebrand
factor  type  C  domain,  a  thrombospondin1  domain,  and  a
cystin knot motif. All motifs contribute to the broad range of
different  molecular  and  biologic  functions  by  enabling
interaction of CTGF with a large number of cytokines, cell
surface receptors or proteoglycans. The contribution of CTGF
to  cell  proliferation  and  extracellular  matrix  (ECM)
remodelling [3,4], the molecular interaction with cytokines
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like bone morphogenetic proteins (BMPs) or transforming
growth factor beta (TGF-β) [5] or the binding to proteoglycans
like  heparin  [6]  and  different  cell  surface  receptors  like
integrins  [7-9]  led  to  the  notation  of  CTGF  as  a
“multifunctional matrixcellular protein” in fibroblasts [10].
One of the most noted functions is its role as a transmitter in
the activation of fibroblasts induced by TGF-β. In this context,
CTGF is an immediate early gene and downstream mediator
of TGF-β thereby playing a key role in biologic processes like
wound healing or in pathological situations like fibrosis by
promoting  fibroblast  proliferation,  inducing  ECM
remodelling, and initiating myofibroblast differentiation [3,
4,11].
The  relevance  of  CTGF  in  the  human  eye  has  been
studied, but only little is known about the effect of CTGF, in
particular, which genes or biologic processes are affected by
CTGF. But identification of CTGF on the protein level in
different eye fluids, like aqueous humor [12] and tear fluid of
healthy individuals [13], as well as the increase of CTGF
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53levels in pathological situations correlates with its important
role in proliferation and wounding also in the human eye.
Conformingly, CTGF mRNA is expressed in corneal scar
tissue  and  membranes  in  activated  corneal  fibroblasts,
retrocorneal membranes, and subepithelial membranes, but
not  in  control  corneas  [14].  A  role  of  CTGF  in  the
pathogenesis  of  conjunctival  scarring  in  ocular  cicatricial
pemphigoid (OCP) also has been shown. Cultured fibroblasts
isolated from the conjunctiva of patients with OCP showed
elevated CTGF expression on mRNA and protein levels [15].
CTGF expression levels are also elevated in patient’s eyes
having  proliferative  vitreoretinal  diseases,  such  as
proliferative  diabetic  retinopathy  and  proliferative
vitreoretinopathy  (PVR)  [16].  The  role  of  CTGF  in  scar
formation after glaucoma filtering surgery (GFS) has been
analyzed in a rabbit animal model. CTGF and TGF-beta were
maximally expressed by day 5 after surgery and both proteins
are present in the bleb tissues after GFS [17].
To  identify  genes  which  are  regulated  upon
administration of CTGF, we analyzed the gene expression
profile  of  control  and  hCTGF  stimulated  HTFs  using
affymetrixTM  oligonucleotide  arrays.  The  results  show  the
induction of a wound healing and inflammatory response in
light  of  the  upregulation  of  inflammatory  cytokines,  anti-
apoptotic  and  proliferative  genes,  and  components  of  the
ECM.
METHODS
Cell culture: Small tenon biopsy samples were obtained from
standard intraocular surgery. The tenets of the Declaration of
Helsinki were followed, and an institutional ethics committee
approval had been granted. Primary human tenon fibroblasts
(HTFs) were cultured as an expansion culture of the human
tenon explants and were maintained in the logarithmic growth
phase. For all experiments, only cells from passages 2 to 8
were used. Primary HTFs and the human cell line HEK293T
were cultured in Dulbecco’s modified Eagle medium (Gibco
Life Technologies, Karlsruhe, Germany) supplemented with
10%  heat-inactivated  fetal  calf  serum  (Gibco  Life
Technologies),  100  U/ml  penicillin,  and  100  µg/ml
streptomycin (Biochrom, Berlin, Germany).
CTGF  protein  expression  and  purification:  The  cDNA
encoding  for  full-length  rhCTGF  (aa  1–349;  Swiss-Prot
P29279) was cloned into the eukaryotic expression vector
pCEP4 (Invitrogen, Darmstadt, Germany). HEK293T cells
were  transfected  with  the  expression  plasmid  using
lipofectamineTM (Invitrogen) according to the protocol in the
supplemental section. Stable clones were selected by adding
hygromycin B (Invitrogen). For protein expression, selected
clones  were  cultured  in  serum-free  DMEM  medium.
Recombinant  hCTGF  protein  was  purified  from  the
supernatant  employing  a  three-step  purification  protocol.
First, rhCTGF was isolated from the supernatant by heparin-
sepharose chromatography using the specific affinity of the
cystin-knot domain to heparin [6] subsequently followed by
BMP-2 (bone morphogenetic protein 2) affinity [5,18] and
S200 size exclusion chromatography. The purity of protein
was analyzed by SDS–PAGE and western blot analysis.
SDS–PAGE and western blot analysis: Protein samples were
analyzed by SDS–PAGE using a 12% acrylamide gel and
visualized by coomassie blue staining. For western blotting,
proteins  were  separated  by  SDS–PAGE  and  subsequently
transferred to nitrocellulose membrane (Whatman, Schleicher
&  Schuell,  Dassel,  Germany)  using  a  semidry  blotting
chamber. The membrane was incubated in blocking buffer
(5% BSA, 0.05% Tween-20 in 10 mM Tris, 100 mM NaCl,
pH 7.4) for 1 h and then incubated with a polyclonal goat α-
CTGF  antibody  (1:500  dilution  in  blocking  buffer;  Santa
Cruz,  Heidelberg,  Germany)  for  1  h.  The  membrane  was
washed (10 mM Tris, 100 mM NaCl and 0.05% Tween-20)
three times and incubated with a secondary antibody (rabbit
α-goat horseradish peroxidase conjugated; diluted 1:5000 in
blocking buffer; Santa Cruz) for 1 h at room temperature.
Detection was performed using enhanced chemiluminescence
by the addition of ECL Plus reagents (Amersham-Pharmacia,
Freiburg, Germany).
Biosensor  measurement:  A  BIACORE®2000  system
(BIAcore, Freiburg, Germany) was used for all biosensor
experiments.  Biotinylated  BMP-2  was  immobilized  to  a
streptavidin-coated biosensor CM5 chip at a density of about
500 resonance units (RU). BMP-2 used for these experiments
was expressed and purified as described [19]. Sensorgrams of
the CTGF-BMP-2 interaction were recorded at a flow-rate of
10 μl min−1 at 25 °C. The association phase was set to five and
the dissociation phase to three min. After each cycle, the
biosensor chip was regenerated with 4 M MgCl2. Binding
affinities were calculated by fitting the kinetic data to a 1:1
Langmuir binding model using the BIAevaluation software
2.2.4.  Binding  constants  were  determined  from  two
independent experiments using at least six different ligand
concentrations. Standard deviations for the calculated KD-
values were found to below 50%.
Fibroblast proliferation assay: Cells were seeded at a density
of  6,000  cells/cm2  using  a  96  microwell  plate  and  were
allowed to adhere for 16 h. Cells were serum-starved for 24 h
in DMEM (3% FCS) and subsequently stimulated for 48 h
with different concentrations of rhCTGF (10–6,000 ng/ml).
Cells growing in the presence of 10% FCS were used as a
reference to show the maximal proliferation of HTFs under
normal culture conditions. During the final 24 h 10 μl [3H]-
thymidine (0.25 μCi; Amersham-Pharmacia) was added to
each well. The cells were harvested on fiber mats (Scatron,
Lierbyen,  Norway)  and  thymidine  incorporation  was
measured  using  a  beta-radioactivity  intelligent  thin  layer
analyzer (RITA). All assays were performed in duplicates and
repeated three times.
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1x105 HTFs of three different donors were stimulated with
6 µg/ml rhCTGF for 48 h as described before. Total RNA was
extracted from cells using the RNeasy Mini Kit according to
the manufacturer's instructions (Qiagen, Hilden, Germany).
RNA  integrity  and  comparability  was  tested  using  a
BioAnalyzer  (Agilent,  Santa  Clara,  CA).  RNA  integrity
numbers (RIN) for the isolated RNAs ranged between 9.7 and
10,  indicating  excellent  integrity.  Reverse  transcription,
second-strand synthesis, clean-up of double-stranded cDNA
and  subsequent  synthesis  of  biotin-labeled  cRNA  was
performed  according  to  Affymetrix  protocols  (One-Cycle
cDNA synthesis Kit / IVT Labeling Kit; Affymetrix, Santa
Clara, CA) starting from 2 μg of total RNA. From each sample
15 µg of adjusted cRNA were hybridized to a human Genome
U133 Plus 2.0 GeneChip® and visualized with a GeneChip
Figure 1. SDS–PAGE and western blot of rhCTGF. rhCTGF was
expressed in HEK293T cells and purified by heparin and BMP-2
affinity chromatography. The purified protein (2 μg) was analyzed
by (A) coomassie blue stained SDS–PAGE and (B) western blot
using a α-CTGF antibody.
Scanner 3000 (Affymetrix). The RNA expression profiles of
the three different donors were analyzed separately.
Data analysis: Data were analyzed using different R packages
from  the  Bioconductor  project.  Signal  intensities  were
normalized by variance stabilization [20]. The quality of all
data sets was tested by density plot and RNA degradation plot.
Statistical analysis for selection of differentially expressed
genes  was  performed  using  the  limma  package  (Linear
Models for Microarray Analysis). The core algorithm of the
limma package is an implementation of the empirical Bayes
linear modeling approach of Smyth [21,22] that can be used
for stable analysis even for smaller sample sizes.
Real-Time reverse transcription polymerase chain reaction
(RT–PCR): For RT–PCR analysis HTFs were stimulated with
6 µg/ml rhCTGF for 48 h in a 24-well plate as described
before. Total RNA was harvested using RNeasy spin columns
(Qiagen) according to the manufacturer’s recommendations.
First-strand cDNA was synthesized using M-MLV Reverse
Transcriptase (Promega, Mannheim, Germany) at 42 °C for 1
h using 1 µg total RNA. RT–PCR was conducted in a 96-well
microtiter  plate  using  the  iCycler  instrument  (Bio-Rad,
Munich,  Germany).  A  total  reaction  volume  of  25  µl
contained 50 ng of cDNA assuming 100% yield in the cDNA
synthesis reaction), 0.4 µM of each primer, 240 µM dNTP mix
(Invitrogen), 1× Taq polymerase reaction buffer (Promega),
2 Units Taq polymerase (Promega), FITC and SYBRgreen
(Sigma-Aldrich, St. Louis, MO). Cycling conditions included
an initial denaturation step at 95 °C for 3 min, followed by 40
cycles consisting of a 15 s denaturation interval and a one min
interval for annealing and primer extension at 60 °C. The
housekeeping  gene  hypoxanthine-guanine-
phosphoribosyltransferase  1  (HPRT1)  served  as  a
normalization standard. Primer pairs used for RT-PCR are
listed in Table 1.
TABLE 1. RT-PCR PRIMER PAIRS.
Name Primer sequence Melting temp (°C) Product size (bp)
HPRT1 for GACCAGTCAACAGGGGACAT 61.8 194
HPRT1 rev ACACTTCGTGGGGTCCTTTT 61.0  
TNFα for CCCGAGTGACAAGCCTGTAG 62.0 151
TNFα rev GAGGTACAGGCCCTCTGATG 62.0  
IL1β for GGGCCTCAAGGAAAAGAATC 58.3 205
IL1β rev TTCTGCTTGAGAGGTGCTGA 59.5  
IL6 for AGGAGACTTGCCTGGTGAAA 60.3 180
IL6 rev CAGGGGTGGTTATTGCATCT 58.6  
IL8 for AGGGTTGCCAGATGCAATAC 58.3 213
IL8 rev CCTTGGCCTCAATTTTGCTA 56.4  
CXCL1 for GAAAGCTTGCCTCAATCCTG 57.5 214
CXCL1 rev TCCTAAGCGATGCTCAAACA 56.7  
CXCL6 for GGGAAGCAAGTTTGTCTGGA 59.4 237
CXCL6 rev CTTTCCCCCACACTCTTCAA 59.8  
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hCTGF binds specifically to BMP-2: To study the biologic
effects  on  human  tenon  fibroblasts  (HTFs)  recombinant
hCTGF  was  prepared  as  described  above.  Purity  and
homogeneity of the protein was analyzed by SDS–PAGE and
western blot (Figure 1A,B). Recombinant CTGF appears as
two bands with an electrophoretic mobility corresponding to
36 kDa (unglycosylated) and 38 kDa (glycosylated isoform)
in  gel  electrophoresis  analysis  as  reported  [4].  Biologic
activity  of  recombinant  hCTGF  was  tested  by  binding  to
immobilized BMP-2 using BiacoreTM technology. Specific
binding  of  hCTGF  to  immobilized  BMP-2  revealed  an
apparent KD value of 400 nM consistent with previous results
obtained for binding of CTGF [5] to the BMP-2 homolog
BMP-4 (Figure 2).
hCTGF  induces  proliferation  in  human  primary  tenon
fibroblast: In a second experiment the effect of hCTGF on cell
proliferation was analyzed in a cell based assay measuring
[3H]-thymidine incorporation into DNA. After 48 h hCTGF
treated HTFs showed a fourfold increased DNA synthesis
compared to negative control (Figure 3A). In all experiments,
addition of hCTGF induced the same proliferation effect as
observed  for  the  FCS  control.  Additionally,  a  time  series
experiment  was  performed  to  show  that  the  experimental
setup  chosen  for  gene  expression  analysis  represents  the
optimal time point leading to a maximal proliferation rate.
After 24 h HTFs exhibited slightly increased DNA synthesis
(1.5 - twofold) with the peak levels after 48 h (3 - sixfold). In
all  experiments  proliferation/DNA  synthesis  strongly
decreased after 72 h with DNA synthesis in most cases being
below the value for 24 h incubation (Figure 3B).
Gene expression profiling of hCTGF stimulated human tenon
fibroblasts: In the past ten years the relevance of CTGF for
fibroblast biology with respect to proliferation, extracellular
matrix production, wound healing, and diseases like fibrosis,
has been shown [10,23,24]. Therefore we focused in our study
on the relevance and influence of hCTGF on genes being
differentially expressed in tenon fibroblasts of the human eye.
After  CTGF  stimulation  for  48  h,  9.000  to  10.000
transcripts out of 18.400 analyzed transcripts were expressed.
Of those a total of 110 transcripts are differentially expressed
twofold or higher, for 21 of them the transcriptional difference
exceeds more than threefold compared to the unstimulated
control.  Interestingly,  the  group  of  genes  in  fibroblasts
showing  upregulated  expression  upon  hCTGF  stimulation
was significantly larger, with 92 transcripts compared to 18
genes  being  down-regulated.  The  strongest  upregulation
observed is 14.3 fold, the strongest down-regulation 3.1 fold
Figure  2.  Sensorgrams  of  BIAcore
measurements. Binding of CTGF at the
indicated concentrations to immobilized
BMP-2 was recorded at a flow-rate of 10
μl/min at 25 °C. The association phase
was set to five and the dissociation phase
to three min. Specific binding of hCTGF
to  immobilized  BMP-2  reveals  an
apparent KD value of ~400 nM.
Figure 3. rhCTGF induced proliferation
in primary tenon fibroblasts. HTFs were
starved for 24 h and (A) subsequently
stimulated  for  48  h  with  increasing
CTGF concentrations up to 4 μg/ml and
10% FCS as positive control and (B) for
different time points between 24 and 72
h  with  a  concentration  of  4  μg/ml
rhCTGF.  In  both  experiments  [3H]-
thymidine  DNA  incorporation  was
measured  after  a  24  h  incubation
intervall by RITA.
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56compared to control cells. The ten most strongly up- and
down-regulated genes are shown in Table 2 and Table 3.
To compose functional groups of genes allowing for a
better insight into the biologic functions, the differentially
expressed genes were analyzed and categorized with gene
ontology (GO) [25]. The three main selection parameters of
GO are molecular function, biologic process, and cellular
component. The three groups can be subdivided into further
functional subgroups, hierarchically classified and facilitate a
better description of the biologic incidents. From the genes
identified the 350 strongest up- and the 150 strongest down-
regulated genes were selected and categorized via GO.
Mainly three categories are influenced: 1. Wound healing
and  inflammatory  response;  2.  Proliferation  and  anti-
apoptosis;  3.  Extracellular  matrix  remodelling.  In  the
following we describe selected genes of each category or
biologic process representative for each group.
hCTGF initiate wound healing and inflammatory response in
HTFs: The GO analysis reveals mainly the initiation of a
strong inflammatory and wounding response. Some of the
strongest upregulated genes are members of the CC or CXC
cytokine  families,  e.g.,  interleukin  6  (IL-6),  interleukin  8
(IL-8),  chemokine  (C-X-C  motif)  ligand  6  (CXCL6),  and
chemokine (C-C motif) ligand 2 (CCL2; Figure 4A). The
initial immune response is boosted by the elevated expression
of complement cascade elements like complement factor B
and complement component C3. Complement component C3
plays a key role in the activation of the complement system
and  is  important  for  both,  classical  and  alternative,
complement  activation  pathways  [26].  Also  the  elevated
expression  of  the  bradykinin  receptor  B1  indicates  a
wounding and inflammatory response. The receptor is usually
de novo synthesized upon tissue injury and its activation is
part of the inflammatory response [27].
Array results were validated by analyzing six selected
genes of the category “inflammatory and wounding response”
(TNF-alpha, IL-1, IL-6, IL-8, CXCL-1, and CXCL-6). On the
one  hand  we  tested  the  RNA  probes  measured  by
affymetrixTM oligonucleotide arrays and on the other hand we
analyzed the RNA from one additional experiment in each
case for all three donors. The array results could be confirmed
for all six genes (Figure 5).
CTGF  induced  genes  mediate  proliferation  and  anti-
apoptosis  in  HTFs:  Besides  the  wound  healing  and
TABLE 2. TOP 10 UPREGULATED GENES IN HTFS AFTER HCTGF STIMULATION.
Number Gene title Gene symbol Ratio p value
1 chemokine (C-X-C motif) ligand 6 CXCL6 14.3 0.01
2 chemokine (C-X-C motif) ligand 1 CXCL1 9.4 0.15
3 interleukin 8 IL8 5.6 0.18
4 tumor necrosis factor, alpha-induced protein 6 TNFAIP6 5.0 0.18
5 interleukin 6 (interferon, beta 2) IL6 4.9 0.18
6 serpin peptidase inhibitor, clade E SERPINE1 4.7 0.05
7 chemokine (C-C motif) ligand 2 CCL2 4.3 0.05
8 kinesin family member 20A KIF20A 4.1 0.19
9 interferon, alpha-inducible protein (clone IFI-6–16) G1P3 3.9 0.18
10 ribonucleotide reductase M2 polypeptide RRM2 3.3 0.37
TABLE 3. TOP 10 DOWN-REGULATED GENES IN HTFS AFTER HCTGF STIMULATION.
Number Gene title Gene symbol Ratio p value
1 platelet derived growth factor D PDGFD −3.1 0.30
2 osteoglycin (osteoinductive factor, mimecan) OGN −3.0 0.08
3 osteomodulin OMD −3.0 0.23
4 chemokine (C-C motif) receptor-like 1 CCRL1 −2.7 0.24
5 SRY (sex determining region Y)-box 4 SOX4 −2.5 0.05
6 matrix Gla protein MGP −2.4 0.05
7 Ras association (RalGDS/AF-6) domain family 2 RASSF2 −2.2 0.23
8 selenoprotein P, plasma, 1 SEPP1 −2.2 0.18
9 alcohol dehydrogenase IB (class I), beta polypeptide ADH1B −2.2 0.41
10 v-maf musculoaponeurotic fibrosarcoma oncogene
homolog B
MAFB −2.2 0.15
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57inflammatory  response  regulation  and  facilitation  of  cell
proliferation was the strongest biologic activity found (Figure
4D). The proliferative effect of hCTGF in HTVs seems to be
transmitted via two different ways. First, hCTGF induces a
subset of genes directly responsible for proliferation and cell
division by influencing cell cycle check points such as the two
cyclins A2 und B1. Both promote cell proliferation [28,29]
The ubiquitin conjugating enzyme E2C encodes a member of
the  E2  ubiquitin-conjugating  enzyme  family.  It  is  also
required for cell cycle progression [30,31].
Second, CTGF induces a survival program consisting of
genes  with  anti-apoptotic  properties  (Figure  4C).  As  an
example,  Survivin  is  a  member  of  the  inhibitor  of  the
apoptosis  (IAP)  gene  family,  which  encodes  negative
regulatory proteins preventing apoptotic cell death [32]. The
highest differentially expressed transcript out of this category
is  the  interferon  alpha-inducible  protein  6  encoding  the
protein G1P3, which can restore the induction of apoptosis
[33].
Extracellular  matrix  is  remodelled  by  hCTGF:  The  third
strongly regulated group of genes addresses the ECM or genes
that  are  involved  in  its  modeling  process  (Figure  4B).
Remarkably,  a  large  number  of  these  genes  were  down-
regulated  upon  hCTGF  stimulation.  Some  examples  are
decorin, dermatopontin, matrix Gla protein, osteomodulin and
osteoglycin.
The lysyl oxidase belongs to the group of ECM genes
being upregulated. It is an extracellular enzyme that initiates
the cross-linking of collagens and elastin [34]. Another gene
product, the tissue factor pathway inhibitor 2 (TFPI-2), is
responsible for the suppression of matrix invasion activity
[35]  and  for  decreasing  the  amount  of  active  matrix
metalloproteinase  2  [36].  Interestingly,  the  CNN  family
members  Cyr61  and  CTGF  by  itself  seem  also  to  be
upregulated by an autocrine/paracrine positive feedback loop.
DISCUSSION
In the past decade different biologic functions were described
for hCTGF. In fibroblasts TGF-β induced CTGF expression
leads to cell proliferation, myofibroblast differentiation and
extracellular matrix remodelling. These are some of the most
prominent functions, implicating an important role of CTGF
in  biologic  processes  like  wound  healing  or  pathological
situations  like  fibrosis  [11].  Our  results  confirm  the
importance of CTGF also for primary HTFs in the biology of
the human eye. The known CTGF-induced or -dependent
processes  are  reflected  by  the  genes  identified  in  our
affymetrixTM oligonucleotide arrays. Mainly three biologic
Figure  4.  Heat  map  of  differentially
expressed genes in HTFs after CTGF
stimulation.  Differentially  expressed
genes were analyzed and categorized via
“gene  ontology.”  The  selected
categories (A) “response to wounding
and  inflammatory  response,”  (B)
“extracellular  matrix,”  (C)  “anti-
apoptosis,” and (D) “cell proliferation”
are  shown.  Color  represent  measured
signal intensity from lowest (green) to
highest (red) value.
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58processes were shown to be influenced: 1. Wound healing and
inflammation,  2.  Cell  proliferation,  and  3.  Extracellular
matrix remodelling.
Besides the verification of established functions and the
identification of new genes in these categories, mainly two
aspects seem to be important. First, the expression of a subset
of inflammatory genes is induced. Second, CTGF-induced
genes playing normally a key role in bone formation also seem
to be important.
In 2003 Wang et al. [37] described that administration of
recombinant CTGF leads to an elevated DNA synthesis in
primary  porcine  skin  fibroblasts,  but  had  no  effect  on
inflammatory factors like IL-1, IL-6 or tumor necrosis factor
alpha. In contrast, in our model system we could show that
CTGF upregulates the transcription of various members of
different cytokine families (e.g., IL-6,IL-8,CXCL1,CXCL2, or
CXL6). This is of interest, because in diseases in which CTGF
is involved, a strong inflammation reaction is often one factor
that can promote a similar pathology like in fibrosis [38].
Another aspect is that the up-stream inducer of CTGF, TGF-
β, is known to act anti-inflammatory under normal conditions.
But  under  certain  pathologic  conditions,  like  cancer,  this
function  is  reversed  and  TGF-beta  can  enhance  an
inflammatory reaction of tissues or specific cell types [39]. In
this Janus-like scenario CTGF might play an important role.
Dependent  on  the  context  it  promotes  or  inhibits  the
inflammatory response and is by this way a mediator of the
TGF-β induced function and thereby a potential target for new
therapy approaches. But why shows CTGF in human tenon
fibroblasts an inflammatory potential?
One possibility might be due to the cell specificity, thus
CTGF  might  exhibit  different  functions  in  fibroblasts  of
different origin. It has been shown that the cellular response
to CTGF greatly depends on the cell type. In chondrocytes
CTGF induces cell type specific genes like aggrecan and
collagen  X  [40],  whereas  the  gene  collagen  type  I  is  not
regulated. In vascular smooth muscle cells overexpression of
CTGF  reducedes  proliferation  rate  and  induces  apoptosis
[41], the contrary as observed in HTFs.
A second explanation for this phenomenon might be in
the requirement of co-factors. It could be demonstrated for
NRK cells that the induction of cellular responses by CTGF
is co-factor dependent. CTGF alone did not show any effect
in that cellular system, but in the presence of the epidermal
growth factor (EGF), CTGF could promote cell proliferation.
In combination with insulin like growth factor 2 (IGF-2),
administration of CTGF leads to elevated collagen I synthesis
and alpha smooth muscle actin expression [3].
We proofed this hypothesis for HTFs using Real Time
RT–PCR  by  independent  addition  of  both  co-factors.  We
analyzed gene expression at different time points, but neither
the addition of EGF nor IGF-2 had a significant effect on
proliferation, collagen type I or alpha smooth muscle actin
RNA expression (data not shown). However, it cannot be
excluded that HTFs need a different specific factor to show a
proliferative response.
On the other hand, an expression profile analysis with
primary  human  skin  fibroblast  stimulated  with  the  CTGF
homolog Cyr61 is consistent with our gene expression results
[42]. It could be demonstrated that also this angiogenic factor
activates a genetic program for wound healing.Some of the
genes  induced  by  Cyr61  were  also  identified  in  our
experiments (e.g., PAI-1 or uPA). Interestingly, the expression
of  IL-1  beta  was  shown  to  be  upregulated  upon  Cyr61
treatment. IL-1 beta can induce the expression of IL-6 and
IL-8, thus also indicating an inflammatory potential of CTGF.
Figure  5.  Expression  level  of
inflammatory  genes  in  human  tenon
fibroblasts  after  CTGF  stimulation.
HTFs  were  stimulated  with  6  μg/ml
CTGF for 48 h. Total RNA was isolated
and gene expression was analyzed via
affymetrix array. Selected genes out of
the  catagory  “inflammation”  were
validated using real time RT–PCR. The
figure  shows  the  fold  induction
measured  by  affymetrix  arrays
compared to the results of real time RT–
PCR (RT) for every single donor using
the  RNA  used  in  array  analysis.  The
results were additionally validated for
every  donor  in  an  independent
experiment  (donors  were  stimulated
again with CTGF). Isolated RNA was
analyzed  via  RT–PCR  (Repeat).  RT–
PCR  was  performed  twice  for  every
single experiment.
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59Furthermore, similar to our results no regulation of alpha
smooth  muscle  actin  was  observed  after  stimulation  with
Cyr61, although the importance of Cyr61 for alpha smooth
muscle actin expression was shown in previous studies [43].
The discrepancies found for previous publications might
be explained by the nature of CTGF as a “multifunctional
matrixcellular protein.” The ability to interact with a broad
range of different proteins enables CTGF to transmit opposite
and cell-specific functions highly dependent on the context.
The second important observation is the regulation of
genes in fibroblasts by CTGF, which are known to be involved
in  the  process  of  bone  formation.  Osteoglycin  is  a  small
proteoglycan, which can interact and induce ectopic bone
formation in concert with TGF-β [44]. Osteomodulin, also
known as osteoadherin, is a small proteoglycan of the ECM
and was shown to be induced by BMP-2 in the pre-myoblast
cell line C2C12 [45]. The matrix Gla protein is as a powerful
inhibitor of calcification of arteries and cartilage [46]. Two
other important genes for bone formation also upregulated by
CTGF are decorin and dermatopontin. Decorin synthesis is
induced  during  conversion  of  myoblasts  to  osteoblasts  in
response to BMP-2 [47], while dermatopontin inhibits the
BMP-2 induced expression of alkaline phosphatase (ALP) in
C2C12 cells [48]. Furthermore dermatopontin is discussed to
modify the binding properties of TGF-β to decorin [49].
Although the individual role of each of these genes in
HRTs is yet unclear, their regulation by CTGF seems to be
important under normal and pathological conditions. Using
macroarray analysis Vittitow and Borras [50] investigated the
consequences of high liquid pressure versus normal pressure
treatment to cells to identify regulated genes of the trabecular
meshwork. Interestingly, a group of genes being essential in
cartilage and bone physiology was found to be regulated as
well as the genes for matrix Gla protein and osteoglycin,
which were also identified in our study as being regulated by
CTGF.  It  is  known  that  the  application  of  pressure  or
mechanical forces influences cell morphology and leads to an
upregulation of CTGF and subsequently to a change in the
expression of responsive genes [51]. It is of great interest what
roles  these  “bone  specific  genes”  play  in  the  context  of
fibroblast biology and pathology of the human eye.
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